Plasma 25‐Hydroxycholecalciferol in Chronic Renal Failure

Bayard, Françis; Bee, Ph.; That, H. Ton; Jp, Louvet

doi:10.1111/j.1365-2362.1973.tb02213.x

Cited by 39 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although our study was limited to a relatively small number of patients in a single geographical location, and thus the study population may not be representative of the overall CKD population, the fact that a high incidence of vitamin D deficiency has been previously reported by others outside the United States suggests that this may indeed be a common finding [13, 14, 17, 18, 20]. Furthermore, a recent study presented in abstract form at the 2003 American Society of Nephrology meeting reported a high incidence of vitamin D deficiency in patients with stage 3 and 4 CKD in the United States [35].…”

Section: Discussionmentioning

confidence: 99%

Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease

González

Sachdeva²,

Oliver³

et al. 2004

Am J Nephrol

398

292

View full text Add to dashboard Cite

Background: Kidney disease has been identified as a risk factor for vitamin D deficiency in hospitalized patients, and low levels of 25-hydroxyvitamin D have been suggested to be a risk factor for hyperparathyroidism in patients with chronic kidney disease (CKD). However, little is known about the magnitude of vitamin D deficiency in patients with CKD living in the United States. Methods: In this regard, we examined the levels of 25(OH)D in 43 patients with CKD and serum creatinine between 1 and 5 mg/dl (calculated glomerular filtration rate 111–11 ml/min per 1.73 m²) as well as in 103 patients undergoing hemodialysis. Results: In the predialysis patients, we found that 37 of the 43 patients (86%) had suboptimal levels of vitamin D (<30 ng/ml). Regression analysis indicated that there was a negative correlation between 25(OH)D and intact parathyroid hormone (PTH). Alkaline phosphatase showed a similar but less sensitive relationship. Serum albumin levels correlated with 25(OH)D levels. In contrast to findings reported in normal individuals, the levels of calcitriol correlated with those of 25(OH)D in the patients with CKD. In the group undergoing maintenance hemodialyis, we found that 97% of the patients had vitamin D levels in the suboptimal range, and there was no correlation of 25(OH)D levels with either PTH or serum albumin values. These data indicate that vitamin D insufficiency and deficiency are highly prevalent in patients with CKD and may play a role in the development of hyperparathyroidism. The functional significance of low levels of 25(OH)D in patients with stage 5 CKD remains to be determined.

show abstract

Section: Discussionmentioning

confidence: 99%

Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease

González

Sachdeva²,

Oliver³

et al. 2004

Am J Nephrol

398

292

View full text Add to dashboard Cite

show abstract

“…On the other hand, the coexistence of osteoporosis and osteomalacia in the aged was reported (Mizuno et al, 1974), and the role of vitamin D in the pathogenesis of osteoporosis still remained to be further elucidated. Bayard et al (1973) reported the decrease of serum 25-OH-D in uremic patients, while Shen et al (1975) reported the increase of serum 25-OH-D in the patients having uremic osteodystrophy. Although we have confirmed in our experiment no significant changes of serum 25-OH-D3 in uremic patients, it is well considerable that nutritive conditions and intake rates of vitamin D in uremic patients have greatly influenced serum 25-OH-D level.…”

Section: Discussionmentioning

confidence: 99%

Effects of Age and Diseases on Human Serum 25-Hydroxycholecalcif erol Determined by Competitive Protein-Binding Assay

et al. 1976

View full text Add to dashboard Cite

“…Some patients on chronic haemodialysis with osteomalacia have low plasma levels of 25-hydroxy-cholecalciferol (Bayard, Bec, Ton That & Louvet, 1973) and rats with experimental chronic renal failure have lower 25-hydroxy-cholecalciferol levels than their pairfed controls (Russell & Avioli, 1972). In addition, 25-hydroxy-cholecalciferol in doses of 6000 to 12000 i.u.…”

Section: Discussionmentioning

confidence: 99%

The plasma half‐life of antipyrine in chromic uraemic and normal subjects.

Maddocks¹,

Wake²,

Mj³

1975

Brit J Clinical Pharma

View full text Add to dashboard Cite

1. Antipyrine was given intravenously in a dose of 18 mg/kg body weight to twelve patients with chronic renal failure (plasma creatinine greater than 4.9 mg/100 ml) who were not taking drugs and twenty normal subjects. 2. Plasma antipyrine levels were measured by a specific method, the plasma half‐life of the drug was determined and used as an index of drug oxidation. 3. The mean (+/‐ s.d) plasma antipyrine half‐ life in patients with chronic renal failure (7.3 +/‐ 2.0 h) was significantly shorter than in normal subjects (13.2 +/‐ 4.3 h: P less than 0.002). There was no difference in the apparent volume of distribution of antipyrine between the two groups (P greater than 0.6). 4. Pretreatment of five patients with chronic renal failure and seven normal subjects with antipyrine or phenobarbitone for weeks significantly shortened the mean plasma antipyrine half‐life from 7.4 +/‐ 2.5 h to 5.0 +/‐ 1.5 h in uraemics (P less than 0.005) and from 13.2 +/‐ 4.5 h to 6.9 +/‐ 1.5 h in normal subjects (P less than 0.0025).5. These results suggest that oxidation of antipyrine by hepatic microsomal enzymes is increased in patients with chronic renal failure, but a state of maximal induction of these enzymes was not observed. The clinical implication of this finding with regard to the association between liver microsomal enzyme induction and vitamin D resistant osteomalacia is discussed.

show abstract

Plasma 25‐Hydroxycholecalciferol in Chronic Renal Failure

Cited by 39 publications

References 20 publications

Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease

Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease

Effects of Age and Diseases on Human Serum 25-Hydroxycholecalcif erol Determined by Competitive Protein-Binding Assay

The plasma half‐life of antipyrine in chromic uraemic and normal subjects.

Contact Info

Product

Resources

About